Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Black Diamond Therapeutics
Biotech
Servier pays $70M for Black Diamond's deprioritized cancer drug
After cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and $710 million in milestones.
Nick Paul Taylor
Mar 19, 2025 7:53am
Lilly goes all-in on AI with new exec position—Chutes & Ladders
Oct 11, 2024 8:30am
Black Diamond reshuffles execs, drops phase 1 lung cancer drug
Oct 8, 2024 5:36am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
Amgen poaches Moderna CMO—Chutes & Ladders
Jun 16, 2023 9:30am
Former AbbVie R&D chief tapped to run Tessera—Chutes & Ladders
Jun 3, 2022 9:30am
